Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.78 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.73 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.73 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.73 |
| ▸ | POLG | P54098 | 2/20 | 0.69 |
| ▸ | DUT | P33316 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxycytidine Triphosphate SCHEMBL27673667 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL18785037 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL28008985 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL12595481 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL1615548 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL42135 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL12729518 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL29725285 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL29030090 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL29099739 | 0.99 | POLB (0.76) | POLBP2RY2P2RY4P2RY6POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076803-A1 | Method for Library Preparation in Next Generation Sequencing by Enzymatic DNA Fragmentation | Miltenyi Biotec B.V. & Co. KG (DE) | 2024-03-07 | — | — | US | claimed |
| EP-4036248-A1 | METHOD FOR LIBRARY PREPARATION IN NEXT GENERATION SEQUENCING BY ENZYMATIC DNA FRAGMENTATION | Miltenyi Biotec B.V. & Co. KG (DE) | 2022-08-03 | — | — | EP | claimed |
| US-10829812-B1 | Amplification of oligonucleotides containing non-standard nucleotides | NATIONAL SCIENCE FOUNDATION | 2020-11-10 | — | — | US | claimed |
| US-10415088-B1 | In vivo conversion of nucleosides in plasmid DNA | BENNER STEVEN A (US) | 2019-09-17 | — | — | US | claimed |
| EP-2045257-B1 | PROCESS FOR PRODUCING DI(PYRIMIDINE NUCLEOSIDE 5'-)POLYPHOSPHATE | YAMASA CORP (JP) | 2016-08-17 | — | — | EP | claimed |
| US-8193338-B2 | Process for producing di(pyrimidine nucleoside 5'-)polyphosphate | YAMASA CORPORATION (JP) | 2012-06-05 | — | — | US | claimed |
| US-7794936-B1 | Using thymidine analogs to improve replication in an expanded genetic alphabet | BENNER STEVEN ALBERT | 2010-09-14 | — | — | US | claimed |
| US-20100016567-A1 | PROCESS FOR PRODUCING DI(PYRIMIDINE NUCLEOSIDE 5'-)POLYPHOSPHATE | YAMASA CORPORATION (JP) | 2010-01-21 | — | — | US | claimed |
| US-20090233280-A1 | METHOD OF ACQUIRING INFORMATION REGARDING BASE SEQUENCE AND INFORMATION READING DEVICE FOR THE SAME | CANON KABUSHIKI KAISHA (JP) | 2009-09-17 | — | — | US | claimed |
| EP-1590484-B1 | METHOD FOR THE DETECTION OF CYTOSINE METHYLATION PATTERNS WITH HIGH SENSITIVITY | EPIGENOMICS AG (DE) | 2009-08-19 | — | — | EP | claimed |
| EP-2045257-A1 | PROCESS FOR PRODUCING DI(PYRIMIDINE NUCLEOSIDE 5'-)POLYPHOSPHATE | YAMASA CORPORATION (JP) | 2009-04-08 | — | — | EP | claimed |
| US-20060263779-A1 | Method for the detection of cytosine methylation patterns with high sensitivity | EPIGENOMICS AG (DE) | 2006-11-23 | — | — | US | claimed |
| EP-1624059-A2 | Method of producing nucleic acid molecules with reduced secondary structure | Agilent Technologies, Inc. (US) | 2006-02-08 | — | — | EP | claimed |
| EP-1590484-A2 | METHOD FOR THE DETECTION OF CYTOSINE METHYLATION PATTERNS WITH HIGH SENSITIVITY | Epigenomics AG (DE) | 2005-11-02 | — | — | EP | claimed |
| US-20050136673-A1 | CMP slurry | XU WEN-QING (US) | 2005-06-23 | — | — | US | claimed |
| US-20050028450-A1 | CMP slurry | XU WEN-QING (US) | 2005-02-10 | — | — | US | claimed |
| WO-2004067775-A2 | METHOD FOR THE DETECTION OF CYTOSINE METHYLATION PATTERNS WITH HIGH SENSITIVITY | EPIGENOMICS AG (DE) | 2004-08-12 | — | — | WO | claimed |
| US-20040086880-A1 | Method of producing nucleic acid molecules with reduced secondary structure | AGILENT TECHNOLOGIES, INC. | 2004-05-06 | — | — | US | claimed |
| EP-1025115-B1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE FLUORESCENT CONJUGATES, PREPARATION METHOD AND USES | CIS BIO INT (FR) | 2003-06-04 | — | — | EP | claimed |
| US-6340747-B1 | COMPLEXED TO RARE EARTH METAL CRYPTATE LABEL; DETECTION AND ISOLATION OF NUCLEIC ACIDS | CIS BIO INTERNATIONAL (FR) | 2002-01-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10415088-B1 | In vivo conversion of nucleosides in plasmid DNA | PNP, POLN, POLRMT | POLB 11/4885P2RY2 693/4885P2RY4 493/4885 |
| US-20100016567-A1 | PROCESS FOR PRODUCING DI(PYRIMIDINE NUCLEOSIDE 5'-)POLYPHOSPHATE | ITPA, UMPS, NUDT1 | POLB 41/4885P2RY2 368/4885P2RY4 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.